Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
DST-backed researchers from Pune demonstrate targeted gene-silencing approach that significantly inhibits tumor growth with minimal toxicity
The safety profile was described as manageable, though not without notable toxicities
The accepted studies span several critical areas of oncology, including nutrition, genomics, precision medicine, patient-reported outcomes, and community-based cancer care
The approval is supported by results from the Phase 3 SWOG 1826 trial
This marks one of the most closely watched oncology readouts at this year’s medical congress
The conference highlighted research suggesting that deuterium levels may influence key biological processes
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
